<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02600767</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-CGH-2015-204</org_study_id>
    <nct_id>NCT02600767</nct_id>
  </id_info>
  <brief_title>Artemether-lumefantrine for Treatment of P. Falciparum Malaria in Brazil</brief_title>
  <official_title>Evaluating the Efficacy of Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Cruzeiro do Sul, Acre, Brazil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Secretaria Estadual de Saúde do Acre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Evandro Chagas National Institute of Infectious Disease</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an in vivo evaluation of drug efficacy performed in Cruzeiro do Sul, in the state of
      Acre, Brazil. A total of 81 participants ≥5 years old with parasitological confirmation of P.
      falciparum monoinfection will be treated under supervision with artemether-lumefantrine for
      three days, with doses according to the Brazilian guidelines for malaria control. The
      clinical and parasitological parameters will be monitored for a 28-day follow-up period to
      evaluate the efficacy of the combination therapy. A blood sample will be collected on filter
      paper on the first day and on the day of suspected failure to try to differentiate the
      parasite genotypes using techniques based on polymerase chain reactions. The results of this
      efficacy evaluation on the drug combination will help the Brazilian Ministry of Health to
      evaluate the national policy for treatment of malaria caused by P. falciparum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol uses the recommended World Health Organization (WHO) protocol for monitoring
      antimalarial efficacy. Patients with malaria will receive supervised therapy and will be
      monitored for 28 days to check for treatment response, both clinically and parasitologically.
      A total of 81 participants ≥5 years old with parasitological confirmation of P. falciparum
      monoinfection will be treated under supervision with artemether-lumefantrine for three days,
      with doses according to the Brazilian guidelines for malaria control. The clinical and
      parasitological parameters will be monitored for a 28-day follow-up period to evaluate the
      efficacy of the combination therapy. Patients will be asked to come back on Days 2, 3, 7, 14,
      21 and 28 for clinical evaluation and blood tests using microscopy. A blood sample will be
      collected on filter paper on the first day and on the day of suspected failure to try to
      differentiate the parasite genotypes using techniques based on polymerase chain reactions,
      this will allow us to determine if the recurrent infection was reinfection or failure or
      recrudescence. Results of this evaluation will guide treatment policies in Brazil.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Evaluation of the efficacy of artemether and lumefantrine for uncomplicated P. falciparum malaria.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of Malaria Parasites in Blood.</measure>
    <time_frame>28 days</time_frame>
    <description>Investigators will evaluate the percentage of patients who remain free of malaria parasites in the blood during the 28-day follow-up period.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Artemether-Lumefantrine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Three days of standard treatment. This is a standard combination therapy for the treatment of P. falciparum malaria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine combination</intervention_name>
    <description>This is the sole arm in this study and it is the use of the standard combination therapy for treatment of P. falciparum malaria.</description>
    <arm_group_label>Artemether-Lumefantrine</arm_group_label>
    <other_name>Coartem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;= 5 years

          -  body weight &lt; 120kg

          -  documented fever (axillary temperature ≥37.5o C) or history of fever in the previous
             48 hours in the absence of other obvious causes of fever, such as pneumonia, middle
             ear infection, etc.

          -  monoinfection by P. falciparum with parasitemia between 250 and 200,000 asexual
             parasites/µl, as determined by swab and thick peripheral blood smear microscopic exam

          -  patient or parent/caregiver able to comprehend and sign informed consent or permission
             form

          -  patients aged 7-17 years able to provide assent, patients aged 5-6 years do not
             require assent

          -  willingness to return to the clinic and/or accept home visits for regular check-ups
             during the 28-day follow-up period

          -  hemoglobin level ≥8 g/dl

        Exclusion Criteria

          -  presence of malaria danger signs (inability to drink, vomiting (more than twice in the
             previous 24 hours), recent history of seizures (one or more in the previous 24 hours),
             altered level of consciousness, inability to sit or stand up); presence of signs of
             severe malaria (altered level of consciousness, psychomotor alteration, seizure,
             torpor and irreversible coma), severe anemia (hematocrit &lt; 15% or clinical signs,
             hemoglobin &lt;5 g/dl), renal failure (serum creatinine &gt; 3 mg/dl or clinical signs),
             pulmonary edema, hypoglycemia (blood glucose &lt; 40 mg/dl or clinical signs), shock
             (systolic blood pressure &lt; 70 mmHg for adults; &lt; 50 mmHg for children), spontaneous
             hemorrhage/disseminated intravascular coagulation, repeated generalized seizures,
             acidemia/acidosis (clinical signs), macroscopic hemoglobinuria, and jaundice.

          -  history of chronic or severe underlying diseases (e.g. heart, renal or liver diseases,
             HIV/AIDS, tuberculosis, malnourishment)

          -  history of hypersensitivity to AL

          -  current pregnancy (history of current pregnancy or positive pregnancy test)

          -  use of any antimalarial drug in the previous 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Macedo de Oliveira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital do Jurua</name>
      <address>
        <city>Cruzeiro do Sul</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2015</study_first_submitted>
  <study_first_submitted_qc>November 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2015</study_first_posted>
  <results_first_submitted>May 17, 2017</results_first_submitted>
  <results_first_submitted_qc>May 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2017</results_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Artemether-Lumefantrine</title>
          <description>Three days of standard treatment. This is a standard combination therapy for the treatment of P. falciparum malaria.
Artemether-lumefantrine combination: This is the sole arm in this study and it is the use of the standard combination therapy for treatment of P. falciparum malaria.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Artemether-Lumefantrine</title>
          <description>Three days of standard treatment. This is a standard combination therapy for the treatment of P. falciparum malaria.
Artemether-lumefantrine combination: This is the sole arm in this study and it is the use of the standard combination therapy for treatment of P. falciparum malaria.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="5" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absence of Malaria Parasites in Blood.</title>
        <description>Investigators will evaluate the percentage of patients who remain free of malaria parasites in the blood during the 28-day follow-up period.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Artemether-Lumefantrine</title>
            <description>Three days of standard treatment. This is a standard combination therapy for the treatment of P. falciparum malaria.
Artemether-lumefantrine combination: This is the sole arm in this study and it is the use of the standard combination therapy for treatment of P. falciparum malaria.</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Malaria Parasites in Blood.</title>
          <description>Investigators will evaluate the percentage of patients who remain free of malaria parasites in the blood during the 28-day follow-up period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Artemether-Lumefantrine</title>
          <description>Three days of standard treatment. This is a standard combination therapy for the treatment of P. falciparum malaria.
Artemether-lumefantrine combination: This is the sole arm in this study and it is the use of the standard combination therapy for treatment of P. falciparum malaria.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alexandre Macedo de Oliveira</name_or_title>
      <organization>CDC</organization>
      <phone>404 718 4751</phone>
      <email>acq7@cdc.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

